Nuclidium Raises $98M Series B to Revolutionize Precision Oncology with Its Innovative CuTrace™ Platform

Nuclidium is thrilled to announce a significant milestone in its journey to redefine precision oncology—a funding raise of $98,000,000 that will accelerate its mission to deliver highly accurate and accessible cancer treatments. This substantial investment reflects not only trust in Nuclidium’s innovative approach but also the growing recognition of the transformative potential of copper-based radiopharmaceuticals. By harnessing its cutting-edge CuTraceTM platform, Nuclidium continues to pioneer the fusion of copper radiometals with a diverse range of cancer-specific targeting molecules, enabling the rapid development of a revolutionary portfolio of diagnostic and therapeutic solutions. The infusion of capital will empower Nuclidium to scale its research and development initiatives, optimize manufacturing processes, and expand distribution capabilities to ensure that hospitals and patients alike can benefit from this groundbreaking technology. At its core, Nuclidium is committed to bridging the gap between revolutionary science and practical, everyday healthcare solutions. The newly raised funds will be strategically deployed to enhance both the safety and efficacy profiles of its radiopharmaceuticals, tackling current supply limitations and improving economic feasibility for medical facilities. With a distinct "diagnostic to therapeutic" approach that de-risks the development process, the company is well-positioned to deliver precision treatments that are not only innovative but also accessible. As a diverse and interdisciplinary team relentlessly pushing the boundaries of precision radio-oncology, Nuclidium is excited to usher in a new era of cancer care where treatment is as targeted as it is transformative. This funding announcement marks a pivotal step forward in Nuclidium's commitment to improving outcomes for cancer patients around the globe while setting new standards in the field of precision oncology.